Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole

Hatsushi Yamagishi, Tomoyuki Koike, Shuichi Ohara, Toru Horii, Ryousuke Kikuchi, Shigeyuki Kobayashi, Yasuhiko Abe, Katsunori Iijima, Akira Imatani, Kaori Suzuki, Takanori Hishinuma, Junichi Goto, Tooru Shimosegawa

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Aim: To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafutidine, a novel H2, receptor antagonist, with those of the proton pump inhibitor lansoprazole (LPZ) 30 mg. Methods: Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug. Results: The median intragastric pH was significantly higher in individuals who received lafutidine 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg. Conclusion: In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidine than by LPZ.

Original languageEnglish
Pages (from-to)2406-2410
Number of pages5
JournalWorld Journal of Gastroenterology
Issue number15
Publication statusPublished - 2008 Apr 21


  • Antisecretory activity
  • H receptor antagonists
  • Lafutidine
  • Lansoprazole
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Stronger inhibition of gastric acid secretion by lafutidine, a novel H<sub>2</sub> receptor antagonist, than by the proton pump inhibitor lansoprazole'. Together they form a unique fingerprint.

Cite this